Please note that these reports are recommended only for Whole Genome Test with 30X and up coverage
(Not compatible with WGL Longreads sequencing test)
The Multiple Myeloma Reportis based on Whole Genome Sequencing Test. As such, it analyzesall Common and Rare Variantsassociated with Multiple Myeloma instead of a limited set of genes, like old genetic target panels.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help you fight infections by making antibodies that recognize and attack germs.
Along with environmental factors,Genetics plays a key rolein the regulation of Multiple Myeloma.
We use a cutting-edge form of technology that not even the most advanced hospitals can provide and that allows us to sequenced your entire DNA with unparalleled precision, instead of focusing on only small parts of the DNA.
Our Sequencing Center is located in L'Aquila, Italy, and with its 900 square-meter fully dedicated to Whole Genome Sequencing is considered Europe's largest private NGS laboratory.
We perform all our analysis internally and thanks to our high-throughput next generation sequencing (NGS) equipment we guarantee superior quality.
Your sample and data will stay in the European Union (also if you are a US resident) and is protected by the EU General Data Protection Regulation (GDPR). Our technology offers data protection improvements not required by law but considered best practices in the industry.